Dr. Jennifer Doudna, a Nobel laureate renowned for her work in CRISPR gene editing, speaks with Bloomberg Tech about Scribe Therapeutics’ recent $128.7 million IPO. The funding will support the company’s efforts to develop CRISPR-based therapies targeting heart disease, marking a significant step from academic research to clinical application. Doudna highlights the potential of this technology to address chronic conditions at a genetic level, emphasizing the importance of translating scientific breakthroughs into real-world treatments.
In the interview, she also reflects on the role of artificial intelligence in modern biotechnology, noting that AI serves as a complementary tool rather than a replacement for scientific expertise. Scribe Therapeutics is using these combined advances to accelerate innovation in genomic medicine. The conversation underscores how emerging biotech firms are working to scale CRISPR applications, aiming to deliver transformative therapies to patients across the globe.